Vertex Pharmaceuticals (VRTX) Long-Term Deferred Tax (2017 - 2026)

Vertex Pharmaceuticals has reported Long-Term Deferred Tax for 10 years, with the latest figure at $2.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 15.86% year-over-year to $2.9 billion; the trailing twelve-month figure through Mar 2026 stood at $2.9 billion (up 15.86% YoY), and the FY2025 full-year result was $2.9 billion, up 24.31% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $2.9 billion, up from $2.9 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $2.9 billion in Q1 2026, with the low at $945.5 million in Q1 2022.
• Average Long-Term Deferred Tax over 5 years is $2.0 billion, with a median of $2.0 billion recorded in 2024.
• Year-over-year, Long-Term Deferred Tax jumped 48.71% in 2023 and advanced 15.86% in 2026.
• Tracing VRTX's Long-Term Deferred Tax over 5 years: stood at $1.2 billion in 2022, then soared by 45.33% to $1.8 billion in 2023, then climbed by 28.64% to $2.3 billion in 2024, then climbed by 24.31% to $2.9 billion in 2025, then gained by 1.72% to $2.9 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $2.9 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.9 billion (Q3 2025), per Business Quant data.

Peer Comparison